Annovis Bio rises as FDA approves late-stage Alzheimer's study protocol

Annovis Bio

07/01/2025 14:16

** Shares of drug developer Annovis Bio  ANVS.N  rise 16.8%
to $6.25 premarket
    ** Co says U.S. FDA has accepted co's updated late-stage
Alzheimer's disease study protocol
    ** Updated protocol combines originally proposed 6-month
symptomatic study and 18-month disease-modifying study into a
single trial - co
    ** 5 of 6 brokerages rate the stock "buy" or higher and 1
"hold"; their median PT is $26 - LSEG
    ** Stock declined ~73% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))